Next-Generation Substernal Pacing Lead for Personalized Cardiac Therapy
Legal Citation
Summary of the Inventive Concept
A novel implantable cardioverter-defibrillator system featuring a substernal pacing lead with integrated sensors for real-time cardiac arrhythmia monitoring and an ICD with artificial intelligence for personalized therapy adaptation, enabling more effective and efficient cardiac care.
Background and Problem Solved
The original patent's implantable cardioverter-defibrillator system, while effective, has limitations in providing personalized cardiac therapy. The new inventive concept addresses this limitation by integrating real-time cardiac activity monitoring and artificial intelligence-driven therapy adaptation, enabling more effective and efficient cardiac care.
Detailed Description of the Inventive Concept
The next-generation substernal pacing lead features integrated sensors for real-time monitoring of cardiac arrhythmias, which transmit data to the ICD. The ICD, equipped with an artificial intelligence module, receives sensor data and adjusts therapy accordingly. The system utilizes machine learning algorithms and patient-specific data to adapt pacing and defibrillation protocols, providing personalized cardiac therapy. The ICD also features a communication interface for remote software updates and data analysis, ensuring continuous improvement and optimization.
Novelty and Inventive Step
The integration of real-time cardiac activity monitoring and artificial intelligence-driven therapy adaptation in the substernal pacing lead and ICD, respectively, constitutes a novel and non-obvious improvement over the original patent, enabling more effective and efficient cardiac care.
Alternative Embodiments and Variations
Alternative embodiments may include wearable devices for patient monitoring, cloud-based analytics platforms for remote data analysis, or different sensor configurations for cardiac activity monitoring. Variations may include different AI algorithms, data analysis techniques, or communication protocols.
Potential Commercial Applications and Market
The next-generation substernal pacing lead has significant commercial potential in the cardiac care industry, particularly in the areas of personalized medicine, artificial intelligence, and remote patient monitoring. The target market includes hospitals, clinics, and medical device manufacturers.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical device engineering, specifically implantable cardiac rhythm management systems, requiring advanced knowledge of electrical engineering, biomedical engineering, and cardiac physiology with expertise in sensor integration, signal processing, and adaptive medical technologies
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer with advanced degree, 5-7 years experience in cardiac medical device design, familiar with implantable cardioverter-defibrillator technologies, sensor integration, and emerging machine learning applications in medical device adaptation
Obviousness Rationale
A PHOSITA would recognize that integrating real-time sensor monitoring and adaptive AI technologies into existing ICD systems represents a predictable technological evolution. The source patent's substernal pacing lead provides a foundational platform that naturally suggests enhancement through intelligent monitoring and personalized therapy adaptation. The technical improvements represent incremental advancements using known engineering techniques and readily available computational technologies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,779 |
|---|---|
| Title | Implantable cardioverter-defibrillator (ICD) system including substernal pacing lead |
| Assignee(s) | Medtronic, Inc. |